Ignite Creation Date:
2025-12-25 @ 4:10 AM
Ignite Modification Date:
2025-12-26 @ 3:07 AM
Study NCT ID:
NCT02007720
Status:
TERMINATED
Last Update Posted:
2019-08-02
First Post:
2013-11-20
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Efficacy, Safety and Tolerability of Sexelaxin When Added to Standard Therapy in AHF
Sponsor:
Novartis Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-03-12
Start Date Type:
ACTUAL
Primary Completion Date:
2017-03-27
Primary Completion Date Type:
ACTUAL
Completion Date:
2017-06-16
Completion Date Type:
ACTUAL
First Submit Date:
2013-11-20
First Submit QC Date:
None
Study First Post Date:
2013-12-11
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2018-05-14
Results First Submit QC Date:
None
Results First Post Date:
2019-08-02
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-06-12
Last Update Post Date:
2019-08-02
Last Update Post Date Type:
ACTUAL